Filing Details

Accession Number:
0001104659-20-082854
Form Type:
4/A
Zero Holdings:
No
Publication Time:
2020-07-10 20:28:26
Reporting Period:
2020-01-02
Accepted Time:
2020-07-10 20:28:26
Original Submission Date:
2020-01-06
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1744659 Akero Therapeutics Inc. AKRO () DE
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1687880 Versant Venture Capital Vi, L.p. One Sansome Street, Suite 3630
San Francisco CA 94104
No No Yes No
1777652 Versant Ventures Vi Gp-Gp, Llc One Sansome Street, Suite 3630
San Francisco CA 94104
No No Yes No
1777654 Versant Ventures Vi Gp, L.p. One Sansome Street, Suite 3630
San Francisco CA 94104
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2020-01-02 10,952 $19.89 3,645,633 No 4 S Indirect See footnote
Common Stock Disposition 2020-01-02 3,900 $21.20 3,641,733 No 4 S Indirect See footnote
Common Stock Disposition 2020-01-02 1,000 $22.17 3,640,733 No 4 S Indirect See footnote
Common Stock Disposition 2020-01-02 684,143 $0.00 2,956,590 No 4 J Indirect See footnote
Common Stock Acquisiton 2020-01-02 13,683 $0.00 13,683 No 4 J Indirect See footnote
Common Stock Disposition 2020-01-02 13,683 $0.00 0 No 4 J Indirect See footnote
Common Stock Acquisiton 2020-01-02 11,803 $0.00 11,803 No 4 J Indirect See footnote
Common Stock Disposition 2020-01-02 11,803 $0.00 0 No 4 J Indirect See footnote
Common Stock Disposition 2020-01-03 3,100 $19.18 2,953,490 No 4 S Indirect See footnote
Common Stock Disposition 2020-01-03 100 $20.27 2,953,390 No 4 S Indirect See footnote
Common Stock Disposition 2020-01-06 4,968 $17.68 2,948,422 No 4 S Indirect See footnote
Common Stock Disposition 2020-01-06 6,101 $18.32 2,942,321 No 4 S Indirect See footnote
Common Stock Disposition 2020-01-06 42,323 $19.93 2,899,998 No 4 S Indirect See footnote
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Indirect See footnote
No 4 S Indirect See footnote
No 4 S Indirect See footnote
No 4 J Indirect See footnote
No 4 J Indirect See footnote
No 4 J Indirect See footnote
No 4 J Indirect See footnote
No 4 J Indirect See footnote
No 4 S Indirect See footnote
No 4 S Indirect See footnote
No 4 S Indirect See footnote
No 4 S Indirect See footnote
No 4 S Indirect See footnote
Footnotes
  1. The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan.
  2. These sales were executed in multiple trades at prices ranging from $19.56 to $20.26. The price reported above reflects the weighted average sale price. The reporting persons hereby undertake to provide full information regarding the number of shares and prices at which these sales were effected, upon request, to the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer.
  3. These sales were executed in multiple trades at prices ranging from $20.87 to $21.56. The price reported above reflects the weighted average sale price. The reporting persons hereby undertake to provide full information regarding the number of shares and prices at which these sales were effected, upon request, to the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer.
  4. These sales were executed in multiple trades at prices ranging from $22.00 to $22.25. The price reported above reflects the weighted average sale price. The reporting persons hereby undertake to provide full information regarding the number of shares and prices at which these sales were effected, upon request, to the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer.
  5. Represents a pro-rata in-kind distribution of Common Stock of the Issuer by Versant Venture Capital VI, L.P. ("Versant VI") without consideration to its partners.
  6. Represents a change in the form of ownership of Versant Ventures VI GP, LP ("Versant GP LP") by virtue of the receipt of shares in the pro-rata in-kind distribution of Common Stock of the Issuer for no consideration by Versant VI.
  7. The shares are held by Versant GP LP. Versant Ventures VI GP-GP, LLC ("Versant GP LLC") is the general partner of Versant GP LP and may be deemed to have voting and investment power over the securities held by Versant GP LP and as a result may be deemed to have beneficial ownership over such securities. Versant GP LLC disclaims beneficial ownership over these securities except to the extent of its pecuniary interest therein.
  8. Represents a pro-rata in-kind distribution of Common Stock of the Issuer by Versant GP LP without consideration to its partners.
  9. Represents a change in the form of ownership of Versant GP LLC by virtue of the receipt of shares in the pro-rata in-kind distribution of Common Stock of the Issuer for no consideration by Versant GP LP.
  10. The shares are held by Versant GP LLC.
  11. Represents a pro-rata in-kind distribution of Common Stock of the Issuer by Versant GP LLC without consideration to its members.
  12. These sales were executed in multiple trades at prices ranging from $19.00 to $19.48. The price reported above reflects the weighted average sale price. The reporting persons hereby undertake to provide full information regarding the number of shares and prices at which these sales were effected, upon request, to the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer.
  13. These sales were executed in multiple trades at prices ranging from $20.25 to $20.32. The price reported above reflects the weighted average sale price. The reporting persons hereby undertake to provide full information regarding the number of shares and prices at which these sales were effected, upon request, to the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer.
  14. These sales were executed in multiple trades at prices ranging from $17.00 to $17.98. The price reported above reflects the weighted average sale price. The reporting persons hereby undertake to provide full information regarding the number of shares and prices at which these sales were effected, upon request, to the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer.
  15. These sales were executed in multiple trades at prices ranging from $18.00 to $18.99. The price reported above reflects the weighted average sale price. The reporting persons hereby undertake to provide full information regarding the number of shares and prices at which these sales were effected, upon request, to the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer.
  16. These sales were executed in multiple trades at prices ranging from $19.55 to $20.22. The price reported above reflects the weighted average sale price. The reporting persons hereby undertake to provide full information regarding the number of shares and prices at which these sales were effected, upon request, to the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer.
  17. These shares are owned directly by Versant VI. Versant GP LP is the general partner of Versant VI and Versant GP LLC is the general partner of Versant GP LP and the ultimate general partner of Versant VI. Versant GP LP and Versant GP LLC may be deemed to have voting and investment power over the securities held by Versant VI and as a result may be deemed to have beneficial ownership over such securities. Versant GP LP and Versant GP LLC disclaim beneficial ownership over these securities except to the extent of their respective pecuniary interests therein.